SRPT241220P117000
- 0.00
- 0.000.00%
Sarepta Therapeutics Newsroom
Sarepta Awarded $115.2M in Vyondys 53 Patent Case: Report
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Mizuho Securities Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Sell Rating on Sarepta Therapeutics Due to Limited LGMD Market Potential and Overestimated Elevidys Projections
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
25 U.S. 'Highest Conviction' Stocks – UBS
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
Express News | HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $75 Price Target
Express News | Sarepta Therapeutics Inc - Anticipates Filing for Accelerated Approval of Srp-9003 in 2025
Express News | Sarepta Therapeutics Completes Enrollment in Emergene, a Phase 3 Clinical Study of Srp-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
Sarepta Therapeutics Insider Sold Shares Worth $1,310,820, According to a Recent SEC Filing
Insider Sale: Director at $SRPT (SRPT) Sells 10,500 Shares
Wolfe's Top 12 Shorted Stocks: FSLR, BE, WBA, and More
PepGen Stock Craters 35% on FDA Clinical Hold
Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
FDA's New Accelerated Approval Guidance to Benefit Rare Disease Drug Development, Analysts Believe | NASDAQ:SRPT
Wall Street Analysts See a 47.95% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?